Eli Lilly CEO Dave Ricks discusses upcoming drug breakthroughs, including non-opioid painkillers.
Eli Lilly & Co. Friday said it agreed to buy biopharmaceutical company Dermira Inc. for $18.75 a share, or about $1.1 billion in cash.
Continue Reading Below
The deal represents a scant 2.2 percent premium to Thursday’s closing price of $18.34 for Dermira, but Eli Lilly said it represents a roughly 86 percent premium to the 60-day volume-weighted average trading price for the Menlo Park, Calif., company.
CLICK HERE TO READ MORE ON FOX BUSINESS
Eli Lilly said the acquisition will expand its immunology pipeline with the addition of lebrikizumab, which is being evaluated in a phase 3 study for the treatment of moderate-to-severe atopic dermatitis.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| LLY | ELI LILLY & COMPANY | 136.28 | +0.36 | +0.26% |
| DERM | DERMIRA INC. | 19.09 | +0.75 | +4.09% |
The Indianapolis drugmaker said it expects to complete the acquisition, which isn’t subject to any financing condition, by the end of the first quarter.
MYLAN RECALLS DRUG FOR HEARTBURN, ULCERS OVER CANCER CONCERNS
Dermira shares rose 0.9 percent to $18.51 in light premarket trading Friday.
